These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data? Lunning MA; Horwitz S Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661 [TBL] [Abstract][Full Text] [Related]
6. Novel agents in development for peripheral T-cell lymphoma. O'Connor OA Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580 [TBL] [Abstract][Full Text] [Related]
7. Novel targeted therapies in peripheral T cell lymphoma. Jagadeesh D; Smith MR Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951 [TBL] [Abstract][Full Text] [Related]
8. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma. Marchi E; Raufi AG; O'Connor OA Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883 [TBL] [Abstract][Full Text] [Related]
9. New drug therapies in peripheral T-cell lymphoma. Howman RA; Prince HM Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858 [TBL] [Abstract][Full Text] [Related]
10. Treatment strategies for peripheral T-cell lymphomas. Foss FM Best Pract Res Clin Haematol; 2013 Mar; 26(1):43-56. PubMed ID: 23768640 [TBL] [Abstract][Full Text] [Related]
12. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013 [TBL] [Abstract][Full Text] [Related]
13. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Zain JM Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775 [TBL] [Abstract][Full Text] [Related]
14. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma. Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS; Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877 [TBL] [Abstract][Full Text] [Related]